---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-349482"
form_type: "8-K"
ticker: "RNA"
cik: "0002093101"
company_name: "Atrium Therapeutics, Inc."
filed_at: "2026-08-13T20:50:28+00:00"
generated_at: "2026-08-13T20:51:09.780588+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Atrium Therapeutics Q2 2026: IND cleared for ATR 1072, BMS milestone $15M, cash $263.9M

## Summary
- FDA cleared IND for ATR 1072; Corventis Phase 1/2 trial in PRKAG2 syndrome launched, ~37 participants planned.
- Earned second BMS milestone payment of $15M in August, to be recognized in Q3 2026.
- Q2 2026 collaboration revenue $3.0M; R&D expenses $15.3M; G&A $10.3M.
- Cash, equivalents and short-term investments $263.9M as of June 30, 2026; runway through mid-2028.
- Expect first Corventis participant enrollment by end of 2026; initial data 2H 2027; IND for ATR 1086 in 2027.

## SEC filing metadata
- accession: 0001193125-26-349482
- form_type: 8-K
- ticker: RNA
- cik: 0002093101
- company_name: Atrium Therapeutics, Inc.
- filed_at: 2026-08-13T20:50:28+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2093101/000119312526349482/0001193125-26-349482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2093101/000119312526349482/d149126d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-349482
- JSON: https://secwatch.observer/filing/0001193125-26-349482.json
- Plain text: https://secwatch.observer/filing/0001193125-26-349482.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.